Blinatumomab is an anti-CD3 × anti-CD19 fragment bispecific T-cell engager that links human CD3 + T cells with CD19 + leukemia cells, triggering a cytotoxic immune response and exerting antitumor effects (13). Here, CD19 is linked to leukemia.